Newsroom
Sorted by: Latest
-
Dynamo Software Secures Two Industry Awards for Innovation and Excellence
BOSTON--(BUSINESS WIRE)--Dynamo Software wins awards, including TrustRadius Top Rated Provider in 3 categories, for helping clients work smarter with its AI-powered platform....
-
SS&C GlobeOp Hedge Fund Performance Index and Capital Movement Index
WINDSOR, Conn.--(BUSINESS WIRE)--SS&C GlobeOp Hedge Fund Performance Index: May performance 1.77%; SS&C GlobeOp Capital Movement Index: June net flows advance 0.75%...
-
Supermicro Announces Pricing of Equity and Equity-Linked Financing Transactions To Fund AI Orders
SAN JOSE, Calif.--(BUSINESS WIRE)--Super Micro Computer, Inc. (NASDAQ: SMCI) (“Supermicro” or the “Company”), a Total IT Solution Manufacturer for AI, Cloud, Storage, and 5G/Edge, today announced the pricing of its previously announced series of concurrent equity and equity-linked financing transactions. The gross proceeds of these offerings, together with potential gross proceeds of Supermicro’s $1.25 billion at-the-market, or ATM, offering program for the sale of common stock over time, repre...
-
Dole Expands Year Two of Highly Successful Global Campaign With Minecraft Designed Towards Maximum Performance With New Pineapple-Focused Experience
CHARLOTTE, N.C.--(BUSINESS WIRE)--Dole Food Company has launched the next phase of its partnership with Minecraft, offering new experiences inspired by its 25-year pineapple heritage....
-
Xeris Biopharma Announces Private Exchange of Convertible Notes
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the “Notes”). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing condit...
-
Vivosun präsentiert die Zukunft des KI-gestützten Growings auf der Mary Jane Berlin 2026
BERLIN--(BUSINESS WIRE)--Vivosun, die weltweit führende Marke für Home-Grow-Systeme, präsentiert auf der Mary Jane Berlin 2026 ihre neuesten KI-gestützten Innovationen für den Pflanzenanbau. Die Messe findet vom 11. bis 14. Juni auf dem Berliner Messegelände statt. Besucher können die Zukunft des intelligenten Anbaus am Stand A14 in Halle 18 hautnah erleben. Im Mittelpunkt des diesjährigen Messeauftritts steht der AI GrowHub X42 – die nächste Generation eines smarten Grow-Controllers, der den A...
-
Converteo Launches an International AI and Agentic Systems Offering Dedicated to the Pharma & Life Sciences Industry
PARIS--(BUSINESS WIRE)--Converteo, a leading consulting firm specializing in data and artificial intelligence, today announces the launch of a service and solution offering for production-grade AI dedicated to the Pharma & Life Sciences sector. Since 2024, the pharmaceutical sector has become one of the world's largest investors in AI. In an environment shaped by increasing regulatory demands, cost pressures, and higher expectations for outcomes, Life Sciences companies need to accelerate i...
-
EnerSys Hosts 2026 Investor Day
READING, Pa.--(BUSINESS WIRE)--EnerSys (NYSE: ENS), a global leader in stored energy solutions for industrial, infrastructure, and defense applications, will host an Investor Day in New York City today, Thursday, June 11, 2026, starting at 8:30 a.m. (ET). The formal presentations are expected to conclude at approximately 11:45 a.m. (ET). Shawn O’Connell, President and Chief Executive Officer and Andrea Funk, Executive Vice President and Chief Financial Officer, along with other members of the s...
-
Takeda’s Zasocitinib Significantly Outperforms Deucravacitinib in Head-to-Head Phase 3 Psoriasis Study, Promising to Redefine Oral Treatment Expectations
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) announced positive topline results for the Phase 3, randomized, multicenter, double-blind study comparing zasocitinib (TAK-279), an investigational, next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, to deucravacitinib in adults with moderate-to-severe plaque psoriasis (PsO). In the LATITUDE Atlas (TAK-279-PsO-3004) head-to-head study, zasocitinib demonstrated statistical superiority...
-
Magellan Aerospace Announces Renewal of Normal Course Issuer Bid
MISSISSAUGA, Ontario--(BUSINESS WIRE)--Magellan Aerospace Corporation (“Magellan or Corporation") (TSX: MAL) announced today that the Toronto Stock Exchange has accepted notice filed by Magellan to make a normal course issuer bid (“NCIB”) through facilities of the Toronto Stock Exchange (the “TSX”) and other alternative Canadian trading systems. The notice provides that Magellan may, during the 12 month period commencing June 15, 2026 and ending June 14, 2027, purchase for cancellation up to 2,...